Daito Pharmaceutical: Announcements of individual stocks regarding strengthening capital business partnerships related to China business.
Daito Pharmaceutical: FY May 2024 Financial Results Report [Japan Standard] (consolidated)
Daito Pharmaceutical: Announcements of individual stocks regarding the cancellation of their own shares.
Daito Pharmaceutical: Announcements of individual stocks regarding organizational changes.
Daito Pharmaceutical: Announcements of individual stocks regarding changes in the position of our representative director and the transfer of director positions.
Daito Pharmaceutical: Earnings reports supplementary explanation materials for May 2024 fiscal year.
Daito Pharmaceutical: Report on the Status of Purchases of Treasury Stock by the Company (Based on Article 24-6, Paragraph 1 of the Law)
Daito Pharmaceutical: Change report (exemption share certificates, etc.)
Daito Pharmaceutical: Announcement of revised financial estimates.
Daito Pharmaceutical: Regarding the signing of the "Agreement for Building Partnership" between Dai Co., Ltd. and Nobel Pharma Co., Ltd.
Daito Pharmaceutical: Treasury stock purchase status report (based on Act Section 24-6 (1))
Daito Pharmaceutical: Notice regarding changes in executive officers
Daito Pharmaceutical: Notice regarding the status and completion of share buybacks
Daito Pharmaceutical: Treasury stock purchase status report (based on Act Section 24-6 (1))
Daito Pharmaceutical: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Daito Pharmaceutical: Notice regarding the status of share buybacks
Daito Pharmaceutical: Correction Report (Mass Ownership Report/Change Report)
Dite: Confirmation
Daito: Quarterly Report - 82nd Quarter 3rd Quarter (2023/12/01 - 2024/02/29)
Daito Pharmaceutical: Summary of Financial Results for the 3rd Quarter Ending May 2024 [Japanese GAAP] (Consolidated)
No Data